Russia registers new drug for prostate cancer treatment.

The Federal Biomedical Agency (FMBA) of Russia has just received national registration for a new drug to treat prostate cancer, developed by FMBA experts.

The new drug, called "Rakurs," is a dual-action drug. First, it destroys bone metastases, prolonging the lives of patients in advanced stages. The drug selectively accumulates in bone, including metastatic bone, providing a strong local anticancer effect.

Secondly, the radioactive radium-223 nucleus significantly reduces or eliminates pain, allowing patients to forgo strong painkillers and improving their quality of life. A unique feature of the drug is its selective accumulation in bone tissue, destroying metastases without severely impacting healthy tissue.

Radioactive [223Ra] nuclei are supplied by the "Research Center for Nuclear Reactors" - Russia's largest nuclear energy research and testing complex, belonging to the state corporation Rosatom.

The drug was developed at the FMBA Medical Center for Radiology and Oncology in Dimitrovgrad. The authors say that in the future, this drug could be used to treat metastatic bone lesions and other types of cancer.

Recently, Russia also announced that it will begin clinical trials of the Enteromix cancer vaccine in 2025.

According to Dr. Andrey Kaprin, the chief cancer treatment specialist at the Russian Ministry of Health , all Russian citizens receive free treatment for all types of cancer.

Source: https://nhandan.vn/nga-dang-ky-loai-thuoc-moi-dieu-tri-ung-thu-tuyen-tien-liet-post853023.html